BioNTech’s Oncology Pivot Gathers Pace as €16.8B War Chest Funds a Late-Stage Blitz

BioNTech reveals 100% disease control for Pumitamig in first-line lung cancer, backed by three Phase 3 trials and €16.8B cash, yet shares slide 4% amid investor skepticism and growing competition.

BioNTech is leaning hard into its post-COVID identity. The Mainz-based biotech, still sitting on a €16.8 billion cash pile as of the end of March, has mapped out an ambitious oncology roadmap that extends well beyond the single-asset narratives that often dominate ASCO headlines. With 13 registration-enabling studies now in motion and a $1 billion buyback programme underscoring management’s confidence, the company is trying to convince investors that its cancer pipeline has both depth and durability.

Yet the market remains sceptical for now. The stock slipped 4.3% to €78.80 on Monday, leaving it more than 20% below its 52-week high of €101.90. Even a flurry of positive clinical data and two analyst upgrades failed to reverse the slide. The disconnect between strong science and weak price action suggests the investment community is waiting for proof that Pumitamig and its stablemates can translate early signals into regulatory wins.

Pumitamig Delivers Near-Uniform Disease Control in First-Line Lung Cancer

The centrepiece of the ASCO presentation was Pumitamig, a bispecific antibody targeting both PD-L1 and VEGF-A. Interim data from the ROSETTA Lung-02 study, run jointly with Bristol Myers Squibb, showed a 100% disease control rate across 40 evaluable patients after a median follow?up of 9.0 months. Objective response rates varied sharply by PD-L1 expression: patients with TPS below 1% recorded a 47.6% confirmed ORR, while those with TPS between 1% and 49% hit 77.8%. For the highest expressers (TPS ?50%), the confirmed ORR touched 100%.

The safety profile appears manageable. Grade 3 or higher treatment-emergent adverse events occurred in 48.8% of patients, but only 23.3% were directly attributed to Pumitamig. The discontinuation rate stood at a low 9.3%, a positive signal for a regimen that must compete on tolerability as well as efficacy.

Three Parallel Phase 3 Pathways and a Growing Competitive Threat

BioNTech is not pinning everything on a single trial. The ROSETTA Lung-02 programme is already being expanded into a confirmatory Phase 3 that directly compares Pumitamig plus chemotherapy against the current standard, pembrolizumab plus chemotherapy, with progression?free survival as the primary endpoint. Two additional global Phase 3 studies are under way: ROSETTA Lung-201 tests Pumitamig against durvalumab after concurrent chemoradiation in unresectable stage III disease, while ROSETTA Lung-202 takes on pembrolizumab head?to?head in the first?line, PD?L1?high setting.

That ambition puts BioNTech squarely in the sights of Summit Therapeutics and Akeso, whose bispecific Ivonescimab has already generated pivotal data in China. The Harmoni?3 study in the US is expected to yield results later this year. The PD?1×VEGF race is suddenly crowded, and investors are acutely aware that being early does not guarantee being first to market.

Beyond Lungs: Pipeline Breadth and a Cost?Cutting Backstop

Pumitamig is the headline, but BioNTech’s ASCO presence also highlighted activity in ovarian cancer, with the Phase 2 PRESERVE?004 study of gotistobart plus pembrolizumab showing durable antitumour activity in heavily pre?treated, platinum?resistant disease. Alongside that, antibody?drug conjugates targeting HER3, B7H3 and HER2 are moving through mid?stage development across multiple solid tumour types.

All of this costs money. BioNTech has announced a sweeping restructuring that could affect up to 1,860 positions, with plans to exit sites in Idar?Oberstein, Marburg, Singapore and former CureVac locations. Annual savings are projected to reach roughly €500 million by 2029, freeing up capital to keep the oncology engine running. The balance sheet remains formidable: €16.8 billion in liquidity, plus a $1 billion buyback programme authorised for the next 12 months.

Analysts Turn Bullish, but the Clock Is Ticking

Jefferies reiterated its Buy rating, while UBS upgraded the stock from Neutral to Buy and lifted its price target from $117 to $135. Analyst David Dai described Pumitamig as a “credible candidate for a leading position in its drug class”. The consensus on the Street stands at “Moderate Buy”, with an average target of $129.56. Institutional ownership is just 15.5%, leaving room for increased conviction if late?stage data holds.

UBS forecasts revenue of €2.1 billion in 2026, climbing to €4.44 billion by 2030, with net profit of €398 million expected in that terminal year. Those numbers hinge on the pipeline delivering clinical and commercial traction — and on Pumitamig proving it can outperform established checkpoint inhibitors in the real world.

The next decision point won’t be a stock chart. It will be a data readout from one of the three ongoing Phase 3 trials. BioNTech has the cash, the pipeline breadth and the cost discipline to sustain a long?run oncology bet. What it needs now is the kind of late?stage results that make the market stop looking backward and start looking forward.